Erschienen in:
04.11.2016 | Correspondence
Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration
verfasst von:
Corey T. McMillan, David J. Irwin, Ilya Nasrallah, Jeffrey S. Phillips, Meredith Spindler, Katya Rascovsky, Kylie Ternes, Charles Jester, David A. Wolk, Linda K. Kwong, Virginia M.-Y. Lee, Edward B. Lee, John Q. Trojanowski, Murray Grossman
Erschienen in:
Acta Neuropathologica
|
Ausgabe 6/2016
Einloggen, um Zugang zu erhalten
Excerpt
Corticobasal degeneration (CBD) is characterized by 4-repeat misfolded tau (4Rtau) including astrocytic plaques, threads, and neuronal tangles [
1].
18F-AV-1451 is a PET radioligand that achieves in vivo binding in Alzheimer’s disease (AD) [
8] and autoradiographic evidence of binding to paired helical filaments (PHFs) composed of 3-repeat misfolded tau (3Rtau) and 4Rtau characteristic of AD histopathology [
4,
5,
7]. However, autoradiographic studies of
18F-AV-1451 on CBD postmortem tissue failed to demonstrate binding in cortical regions [
5,
7], though there was minimal pathology in one study (<1.1 % tau-load) [
7]. Another study suggests minimal, but present, autoradiographic binding of
18F-AV-1451 for 4Rtau [
4]. Given mixed autoradiographic evidence in CBD, there is a need for in vivo evaluations of
18F-AV-1451 in patients with pathological confirmation. …
